Eli Lilly Immunology Revenue Reaches $2.6B in H1, Growing 9% Year-Over-Year
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-12. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Expanding non-incretin revenue streams diversifies Eli Lilly's cash flows and reduces reliance on core GLP-1 pricing dynamics.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factEli Lilly's Immunology division generated $2.6 billion in revenues during the first half of 2026, representing 6.1% of total revenues. |
| What else was confirmed? | Reported factImmunology revenues increased 9% year-over-year. |
| Does the valuation support acting? | Interpretation5 stored valuation assumptions for LLY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownEbglyss formulary placement updates — Track US commercial insurance coverage determinations for newly launched immunology assets. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Eli Lilly's Immunology division generated $2.6 billion in revenues during the first half of 2026, representing 6.1% of total revenues.
- · Immunology revenues increased 9% year-over-year.
- · The franchise is led by Taltz and expanding with newer treatments Ebglyss and Omvoh.
- · Growth has been supplemented by acquisitions of DICE, Morphic, and Merida.
Public research record
Research framework · page evidenceCompleted event assessment
portfolio diversification and multi-product revenue growth
| Type | Claim | Scope |
|---|---|---|
| Assumption | Eli Lilly's Immunology division generated $2.6 billion in revenues during the first half of 2026, representing 6.1% of total revenues. | 2026-09-12 |
| Interpretation | portfolio diversification and multi-product revenue growth | LLY |
Countercase, invalidators, and sources
Ebglyss and Omvoh acceleration drives Immunology growth above 15% annually.
- · Ebglyss formulary placement updates — Track US commercial insurance coverage determinations for newly launched immunology assets.
- Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s · 2026-09-11
What remains unresolved
- Base path
- Immunology revenue maintains high single-digit growth, providing steady commercial diversification.
- Adverse path
- Payer pushback and competitive immunology alternatives slow commercial ramp.
- Supportive path
- Ebglyss and Omvoh acceleration drives Immunology growth above 15% annually.
- · Ebglyss formulary placement updates — Track US commercial insurance coverage determinations for newly launched immunology assets.next month
Evidence
- Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s2026-09-11
“Eli Lilly's Immunology division generated $2.6 billion in revenues in H1 2026, up 9% year-over-year, representing 6.1% of total revenues. Led by Taltz, the portfolio is expanding through newer products like Ebglyss and Omvoh”
Supports: Immunology division generated $2.6B in H1 2026, up 9% YoY, representing 6.1% of total revenue.